Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) drives global healthcare innovation through its pharmaceutical, medical technology, and consumer health divisions. This dedicated news hub provides investors and industry professionals with essential updates on regulatory developments, research breakthroughs, and strategic initiatives from one of healthcare's most diversified leaders.
Access real-time press releases and curated analysis covering FDA approvals, clinical trial results, and market expansion efforts. Our repository simplifies tracking JNJ's progress in oncology, immunology, and surgical advancements while maintaining perspective on its long-term corporate strategy.
Key updates include earnings disclosures, product pipeline milestones, and partnership announcements that demonstrate JNJ's commitment to addressing complex health challenges. Bookmark this page for streamlined access to verified information supporting informed decisions about this Dow Jones Industrial Average component.
Johnson & Johnson (NYSE:JNJ) announced that the FDA has approved TREMFYA® (guselkumab) for treating children six years and older weighing at least 40 kg with moderate to severe plaque psoriasis and active psoriatic arthritis. This marks TREMFYA® as the first and only IL-23 inhibitor approved for these pediatric indications.
The approval was based on the Phase 3 PROTOSTAR study, which demonstrated significant efficacy: 56% of patients achieved PASI 90 compared to 16% on placebo, and 66% achieved high skin clearance (IGA score 0/1) versus 16% on placebo at Week 16. The treatment will be administered via subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.
This approval addresses a significant market, targeting approximately 20,000 children under 10 diagnosed with plaque psoriasis annually and 14,000 children affected by psoriatic arthritis.
Vicarious Surgical (NYSE:RBOT) has appointed Joseph Doherty as Chairman of the Board of Directors. Doherty, who joined the board in June 2025, brings extensive healthcare and medical device industry experience, having served as CEO of Worcester City Campus Corporation and President of Scapa Healthcare.
His background includes leadership roles at Olympus Surgical Technologies America and a 24-year tenure at Johnson & Johnson, where he served as Vice President of Integration and Transformation. Doherty holds a BS in Engineering from West Point and an MBA from Nichols College.
Johnson & Johnson (NYSE: JNJ) has received FDA approval for a subcutaneous (SC) induction regimen of TREMFYA® for treating adults with moderate to severe ulcerative colitis (UC). This milestone makes TREMFYA® the first and only IL-23 inhibitor offering both SC and intravenous (IV) induction options for UC and Crohn's disease treatment.
The approval is supported by the Phase 3 ASTRO trial results, where TREMFYA® demonstrated significant improvements versus placebo: 26% vs. 7% in clinical remission and 36% vs. 12% in endoscopic improvement at Week 12. The recommended SC induction dosage is 400 mg at Weeks 0, 4, and 8, with maintenance dosing options of either 100 mg every 8 weeks or 200 mg every 4 weeks.
Additionally, JNJ is initiating a head-to-head study against Skyrizi® in Crohn's disease, highlighting confidence in TREMFYA's clinical profile.
Johnson & Johnson (NYSE:JNJ) announced promising results from its Phase 2 MajesTEC-5 study evaluating TECVAYLI® and DARZALEX FASPRO® in transplant-eligible patients with newly diagnosed multiple myeloma. The immune-based induction regimen demonstrated exceptional efficacy with 100% of evaluable patients achieving minimal residual disease (MRD) negativity following induction therapy.
Key findings include 100% overall response rate across all treatment arms, with 85.7% of patients achieving complete response or better. The treatment showed strong safety profile with manageable side effects, and 96% of patients successfully completed stem cell mobilization. No treatment discontinuations or Grade 5 adverse events were reported.
Johnson & Johnson (NYSE:JNJ) announced significant Phase 3 clinical trial results for icotrokinra, their novel targeted oral peptide for moderate-to-severe plaque psoriasis. The ICONIC-ADVANCE studies demonstrated icotrokinra's superiority over deucravacitinib in skin clearance at Weeks 16 and 24, with adverse event rates similar to placebo.
The ICONIC-LEAD study showed sustained skin clearance through Week 52, with 84% of adult PASI 90 responders maintaining response versus 21% on placebo. In adolescents, 86% achieved PASI 90 response after 52 weeks of treatment. Additionally, JNJ initiated the ICONIC-ASCEND study, the first head-to-head trial comparing an oral treatment (icotrokinra) to an injectable biologic (ustekinumab) in psoriasis treatment.
Johnson & Johnson (NYSE:JNJ) will present 21 abstracts featuring new clinical and real-world data at the 2025 Psych Congress in San Diego from September 17-21. The presentations focus on the company's neuropsychiatry portfolio, including research on major depressive disorder (MDD), treatment-resistant depression (TRD), and schizophrenia.
Key highlights include new Phase 3 data comparing seltorexant with quetiapine XR for MDD with insomnia symptoms, post-hoc analysis of CAPLYTA® in MDD patients with anxious distress, and studies evaluating SPRAVATO® as a monotherapy for TRD. The company will present posters on September 19 and 20, showcasing their commitment to advancing neuropsychiatric treatment options.
Johnson & Johnson (NYSE:JNJ) has received FDA approval for INLEXZO™, a groundbreaking bladder cancer treatment. This first-of-its-kind intravesical drug releasing system (iDRS) provides extended local delivery of gemcitabine for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The SunRISe-1 Phase 2b clinical study demonstrated remarkable efficacy, with 82% of patients achieving complete response and 51% maintaining response for at least one year. INLEXZO™ remains in the bladder for three weeks per treatment cycle for up to 14 cycles, offering a bladder-preserving alternative to surgery.
The FDA granted INLEXZO™ Breakthrough Therapy Designation, Real-Time Oncology Review, and Priority Review. J&J will support patient access through their J&J withMe program, providing cost support and resources.
Johnson & Johnson (NYSE: JNJ) has announced the election of John Morikis, the retired Chairman, President and CEO of The Sherwin-Williams Company, to its Board of Directors. Morikis brings extensive experience in leading multinational organizations and deep understanding of global markets and complex supply chains.
According to Chairman and CEO Joaquin Duato, Morikis's expertise in leveraging technology for innovation will support J&J's mission to advance healthcare innovation. Morikis expressed his enthusiasm about joining the board and contributing to the company's strategy of developing breakthrough treatments while creating shareholder value.
Johnson & Johnson (NYSE: JNJ) announced its participation in the upcoming Bernstein 2nd Annual Healthcare Forum. The company's management will engage in a Fireside Chat on September 24th, 2025, at 1:10 p.m. Eastern Time.
Investors can access a live audio webcast of the presentation through the company's Investor Relations website. An archived version will be available approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) announced groundbreaking results from the Phase 3 MARIPOSA study published in The New England Journal of Medicine. The study evaluated RYBREVANT® plus LAZCLUZE® for first-line treatment of EGFR-mutated non-small cell lung cancer.
The combination therapy demonstrated statistically significant improvement in overall survival compared to osimertinib, with a projected survival exceeding four years - more than one year longer than the current standard of care. At 37.8 months median follow-up, the treatment showed a significant reduction in death risk (HR: 0.75, P=0.005).
The drug combination's triple mode of action targets EGFR mutations, blocks MET, and engages the immune system, potentially changing the disease's natural progression by reducing resistance mechanisms. The safety profile remained consistent with previous analyses, with most adverse events occurring early in treatment.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
